Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | PPP5C | P53041 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.33 |
| ▸ | OGA | O60502 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 3/20 | 0.31 |
| ▸ | CA12 | O43570 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | CD69 | Q07108 | 1/20 | 0.31 |
| ▸ | PPM1B | O75688 | 1/20 | 0.30 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6796708 | 1.00 | TSHR (0.41) | TSHRPPP5CPTPN1OGACA9 | |
| SCHEMBL6723333 | 0.75 | TSHR (0.59) | TSHRPPP5CPTPN1PPM1BPPP1CC | |
| SCHEMBL6723339 | 0.75 | TSHR (0.59) | TSHRPPP5CPTPN1PPM1BPPP1CC | |
| SCHEMBL6796005 | 0.68 | POLB (0.32) | CD69 | |
| SCHEMBL13992898 | 0.67 | CA9 (0.40) | TSHRPTPN1OGACA9CA12 | |
| SCHEMBL15796345 | 0.67 | TSHR (0.68) | TSHRPPP5CPTPN1PPM1BPPP1CC | |
| SCHEMBL8182208 | 0.67 | PTPN1 (0.38) | TSHRPTPN1OGACA9CA12 | |
| SCHEMBL6013528 | 0.67 | PTPN1 (0.38) | TSHRPTPN1OGACA9CA12 | |
| SCHEMBL15258387 | 0.66 | CA9 (0.46) | TSHROGACA9CA12CA1 | |
| SCHEMBL14022075 | 0.66 | OGA (0.44) | TSHRPTPN1OGACA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040152905-A1 | Universal building blocks and support media for synthesis of oligonucleotides and their analogs | ISIS PHARMACEUTICALS, INC. | 2004-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152905-A1 | Universal building blocks and support media for synthesis of oligonucleotides and their analogs | POLM, POLRMT, POLB | TSHR 3397/4885PPP5C 4084/4885PTPN1 2772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.